Bank of New York Mellon
RPTX

Bank of New York Mellon’s Repare Therapeutics RPTX Stock Holding History

Bank of New York Mellon’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6,200
Closed -$213K – 4360
2020
Q4 		$213K Buy
+6,200
New +$185K ﹤0.01% 3958

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Bank of New York Mellon's RPTX Position: Q1 2021 in Review

Bank of New York Mellon sold out of Repare Therapeutics (RPTX) in Q1 2021, closing a stake of 6,200 shares — an estimated $213K sold.

Bank of New York Mellon first reported a position in RPTX in Q4 2020 and held it in 1 quarter. The position peaked at $213K in Q4 2020. 65 funds tracked by Wall St. Rank hold RPTX as of Q1 2021.

  • Bank of New York Mellon reported no remaining Repare Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Bank of New York Mellon sold 6,200 Repare Therapeutics shares in Q1 2021, an estimated $213K.
  • Bank of New York Mellon first reported a position in Repare Therapeutics in Q4 2020 and held it in 1 quarter.
  • Bank of New York Mellon's Repare Therapeutics position peaked at $213K in Q4 2020.
  • 65 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2021.

Based on Bank of New York Mellon's 13F filing for Q1 2021, filed 13 May 2021.